Rafferty Asset Management, LLC Biotechnology

Rafferty Asset Management, LLC

$28.9 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
TNGX Tango Therapeutics, Inc.	$338M	$792,000 0.0% of portfolio	102,955	Q3 2024 Added 41.25%
OCGN Ocugen, Inc.	$197M	$789,000 0.0% of portfolio	797,331	Q3 2024 Reduced 25.97%
FATE Fate Therapeutics Inc	$260M	$750,000 0.0% of portfolio	214,425	Q3 2024 Reduced 14.5%
SVRA Savara Inc	$395M	$712,000 0.0% of portfolio	168,125	Q3 2024 Added 23.95%
ORIC Oric Pharmaceuticals, Inc.	$388M	$661,000 0.0% of portfolio	64,585	Q3 2024 Reduced 44.42%
MDXG Mimedx Group, Inc.	$1.05B	$657,000 0.0% of portfolio	111,222	Q3 2024 Reduced 19.5%
ERAS Erasca, Inc.	$340M	$633,000 0.0% of portfolio	232,170	Q3 2024 New
JAZZ Jazz Pharmaceuticals PLC	$7.7B	$608,000 0.0% of portfolio	5,457	Q3 2024 Added 6.35%
ATXS Astria Therapeutics, Inc.	$150M	$587,000 0.0% of portfolio	53,381	Q3 2024 Reduced 51.39%
CORT Corcept Therapeutics Inc	$6.27B	$532,000 0.0% of portfolio	11,512	Q3 2024 Added 0.6%
ITOS I Teos Therapeutics, Inc.	$291M	$508,000 0.0% of portfolio	49,835	Q3 2024 Added 38.49%
KALV Kal Vista Pharmaceuticals, Inc.	$246M	$507,000 0.0% of portfolio	43,830	Q3 2024 New
YMAB Y M Abs Therapeutics, Inc.	$471M	$460,000 0.0% of portfolio	35,077	Q3 2024 New
RPRX Royalty Pharma PLC	$11.5B	$447,000 0.0% of portfolio	15,827	Q3 2024 Added 5.65%
ABUS Arbutus Biopharma Corp	$511M	$442,000 0.0% of portfolio	115,021	Q3 2024 New
AXSM Axsome Therapeutics, Inc.	$4.16B	$420,000 0.0% of portfolio	4,684	Q3 2024 Reduced 14.48%
SAVA Cassava Sciences Inc	$154M	$367,000 0.0% of portfolio	12,487	Q3 2024 Added 10.93%
EWTX Edgewise Therapeutics, Inc.	$2.03B	$353,000 0.0% of portfolio	13,244	Q3 2024 New
ALEC Alector, Inc.	$212M	$339,000 0.0% of portfolio	72,750	Q3 2024 Reduced 27.71%
ARVN Arvinas, Inc.	$1.3B	$317,000 0.0% of portfolio	12,896	Q3 2024 Reduced 1.39%
LBPH Longboard Pharmaceuticals, Inc.	$814M	$292,000 0.0% of portfolio	8,776	Q3 2024 New
TARS Tarsus Pharmaceuticals, Inc.	$1.32B	$251,000 0.0% of portfolio	7,652	Q3 2024 Added 2.29%
OCUL Ocular Therapeutix, Inc	$750M	$160,000 0.0% of portfolio	18,431	Q3 2024 Reduced 48.4%
FULC Fulcrum Therapeutics, Inc.	$185M	$115,000 0.0% of portfolio	32,368	Q3 2024 New
LQDA Liquidia Corp	$735M	$113,000 0.0% of portfolio	11,323	Q3 2024 Reduced 4.37%
EYPT Eye Point Pharmaceuticals, Inc.	$307M	$91,000 0.0% of portfolio	11,445	Q3 2024 Added 8.85%
NUVB Nuvation Bio Inc.	$628M	$61,000 0.0% of portfolio	26,651	Q3 2024 Added 64.81%
XERS Xeris Biopharma Holdings, Inc.	$432M	$54,000 0.0% of portfolio	19,112	Q3 2024 Reduced 2.17%
SBTX Silverback Therapeutics, Inc.	$0	$0 0.0% of portfolio	81,275	Q3 2024 Reduced 4.74%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.